These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20680660)

  • 1. A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
    Heath EI; Lorusso P; Ramalingam SS; Awada A; Egorin MJ; Besse-Hamer T; Cardoso F; Valdivieso M; Has T; Alland L; Zhou X; Belani CP
    Invest New Drugs; 2011 Dec; 29(6):1426-31. PubMed ID: 20680660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
    Bröker LE; de Vos FY; van Groeningen CJ; Kuenen BC; Gall HE; Woo MH; Voi M; Gietema JA; de Vries EG; Giaccone G
    Clin Cancer Res; 2006 Mar; 12(6):1760-7. PubMed ID: 16551860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
    Bröker LE; Veltkamp SA; Heath EI; Kuenen BC; Gall H; Astier L; Parker S; Kayitalire L; Lorusso PM; Schellens JH; Giaccone G
    Clin Cancer Res; 2007 Jul; 13(13):3906-12. PubMed ID: 17606724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies.
    Plummer R; Ghielmini M; Calvert P; Voi M; Renard J; Gallant G; Gupta E; Calvert H; Sessa C
    Clin Cancer Res; 2002 Sep; 8(9):2788-97. PubMed ID: 12231518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers.
    Chon HS; Kang S; Lee JK; Apte SM; Shahzad MM; Williams-Elson I; Wenham RM
    BMC Cancer; 2017 Jun; 17(1):407. PubMed ID: 28595616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies.
    Chow LQ; Jonker DI; Dy GK; Nicholas G; Fortin C; Patricia D; Adjei AA; Belani CP; Gupta A; Park JS; Zhang S; Sbar EI; Laurie SA
    Cancer Chemother Pharmacol; 2013 May; 71(5):1273-85. PubMed ID: 23468081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer.
    Rizvi NA; Humphrey JS; Ness EA; Johnson MD; Gupta E; Williams K; Daly DJ; Sonnichsen D; Conway D; Marshall J; Hurwitz H
    Clin Cancer Res; 2004 Mar; 10(6):1963-70. PubMed ID: 15041713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer.
    Flaherty KT; Lorusso PM; Demichele A; Abramson VG; Courtney R; Randolph SS; Shaik MN; Wilner KD; O'Dwyer PJ; Schwartz GK
    Clin Cancer Res; 2012 Jan; 18(2):568-76. PubMed ID: 22090362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
    Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
    J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors.
    Peethambaram PP; Hartmann LC; Jonker DJ; de Jonge M; Plummer ER; Martin L; Konner J; Marshall J; Goss GD; Teslenko V; Clemens PL; Cohen LJ; Ahlers CM; Alland L
    Invest New Drugs; 2015 Apr; 33(2):321-31. PubMed ID: 25380635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of weekly paclitaxel and BMS-214662 in patients with advanced solid tumors.
    Bailey HH; Alberti DB; Thomas JP; Mulkerin DL; Binger KA; Gottardis MM; Martell RE; Wilding G
    Clin Cancer Res; 2007 Jun; 13(12):3623-9. PubMed ID: 17510207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
    Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.
    Zhou Q; Gustafson D; Nallapareddy S; Diab S; Leong S; Lewis K; Gore L; Messersmith WA; Treston AM; Eckhardt SG; Sidor C; Camidge DR
    Invest New Drugs; 2011 Apr; 29(2):340-6. PubMed ID: 20084425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Heath EI; Blumenschein GR; Cohen RB; Lorusso PM; Loconte NK; Kim ST; Ruiz-Garcia A; Chao RC; Wilding G
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):703-12. PubMed ID: 21140147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
    Lockhart AC; Bukowski R; Rothenberg ML; Wang KK; Cooper W; Grover J; Appleman L; Mayer PR; Shapiro M; Zhu AX
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):203-9. PubMed ID: 17091249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
    Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
    Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
    Mani S; McDaid H; Hamilton A; Hochster H; Cohen MB; Khabelle D; Griffin T; Lebwohl DE; Liebes L; Muggia F; Horwitz SB
    Clin Cancer Res; 2004 Feb; 10(4):1289-98. PubMed ID: 14977827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.